ERAS vs. FBLG, KMDA, ORGO, AVIR, VRCA, SBTX, NLTX, XOMA, BDTX, and ENTA
Should you be buying Erasca stock or one of its competitors? The main competitors of Erasca include FibroBiologics (FBLG), Kamada (KMDA), Organogenesis (ORGO), Atea Pharmaceuticals (AVIR), Verrica Pharmaceuticals (VRCA), Silverback Therapeutics (SBTX), Neoleukin Therapeutics (NLTX), XOMA (XOMA), Black Diamond Therapeutics (BDTX), and Enanta Pharmaceuticals (ENTA). These companies are all part of the "medical" sector.
FibroBiologics (NASDAQ:FBLG) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, community ranking, media sentiment, dividends and profitability.
Erasca received 16 more outperform votes than FibroBiologics when rated by MarketBeat users.
Erasca's return on equity of 0.00% beat FibroBiologics' return on equity.
67.8% of Erasca shares are owned by institutional investors. 29.8% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Erasca had 5 more articles in the media than FibroBiologics. MarketBeat recorded 6 mentions for Erasca and 1 mentions for FibroBiologics. FibroBiologics' average media sentiment score of 1.38 beat Erasca's score of -0.50 indicating that Erasca is being referred to more favorably in the news media.
Erasca has a consensus price target of $7.83, indicating a potential upside of 271.25%. Given FibroBiologics' higher probable upside, analysts clearly believe Erasca is more favorable than FibroBiologics.
Summary
Erasca beats FibroBiologics on 7 of the 10 factors compared between the two stocks.
Get Erasca News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
